A nanoformulation of siRNA and its role in cancer therapy: In vitro and in vivo evaluation

Cellular and Molecular Biology Letters

Volumn 18, Issue 1, 2013, Pages 120-136

  Jagani, Hitesh ^a   Rao, Josyula Venkata ^a   Palanimuthu, Vasanth Raj ^a,b   Hariharapura, Raghu Chandrashekar ^a   Gang, Sagar ^a  

^a MANIPAL COLLEGE OF PHARMACEUTICAL SCIENCES   (India)

^b AIMST UNIVERSITY   (Malaysia)

Author keywords

Apoptosis; Bcl 2; Cancer; Chitosan; Nanoformulation; RNA interference; siRNA

Indexed keywords

CHITOSAN; CISPLATIN; NANOPARTICLE; PROTEIN BCL 2; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GENE THERAPY; CONTROLLED STUDY; CYTOTOXICITY; DISPERSION; DRUG DOSAGE FORM COMPARISON; ENZYME DEGRADATION; FEMALE; GELATION; GENE DELIVERY SYSTEM; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VIVO GENE TRANSFER; IN VIVO STUDY; IONIC GELATION; MALE; MOLECULARLY TARGETED THERAPY; MOUSE; NANOENCAPSULATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PARTICLE SIZE; POLYDISPERSIVE INDEX; PROTO ONCOGENE; RNA BINDING; RNA INTERFERENCE; RNA STABILITY; TUMOR VOLUME; ZETA POTENTIAL;

MUS;

EID: 84871830648     PISSN: 14258153     EISSN: 16891392     Source Type: Journal    
DOI: 10.2478/s11658-012-0043-2     Document Type: Article

References (44)

1. Lowe, S. W. and Lin, A. W. Apoptosis in cancer. Carcinogenesis21 (2000) 485-496.
2. Chandra, J. and Kaufmann, S. H. Apoptotic pathways in cancer progression and treatment, in: Signal Transduction and Human Disease (Finkel, T. and Gutkind, J. S. Eds.), John Wiley & Sons, Inc., Hoboken, NJ, USA. (2003) 143-170. DOI: 10. 1002/0471482706. ch4.
3. Fulda, S., Meyer, E. and Debatin, K. M. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene21 (2002) 2283-2291.
4. Reed, J. C. Apoptosis-targeted therapies for cancer. Cancer Cell3 (2003) 17-30.
5. Brown, J. M. and Attardi, L. D. The role of apoptosis in cancer development and treatment response. Nat. Rev. Cancer5 (2005) 231-237.
6. Vousden, K. H. Activation of the p53 tumor suppressor protein. Biochim. Biophys. Acta-Rev. Cancer1602 (2002) 47-59.
7. Brown J. M. and Wouters, B. G. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res. 59 (1999) 1391-1404.
8. Banic, B., Nipic, D., Suput, D., Milisav, I. DMSO modulates the pathway of apoptosis triggering. Cell. Mol. Biol. Lett. 16 (2011) 328-341.
9. Adams J. M. and Cory, S. The Bcl-2 protein family: arbiters of cell survival. Science281 (1998) 1322-1345.
10. Cory, S., Huang, D. C. S. and Adams, J. M. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene22 (2003) 8590-8607.
11. Reed, J. C. Dysregulation of apoptosis in cancer. J. Clin. Oncol. 17 (1999) 2941-2961.
12. Oda, E., Ohki, R., Murasawa, H., Nemoto, J., Shibue, T., Yamashita, T., Tokino, T. and Taniguchi, T. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science288 (2000) 1053-1061.
13. Bouillet, P., Cory, S., Zhang, L. C., Strasser, A. and Adams, J. M. Degenerative disorders caused by Bcl-2 deficiency prevented by loss of its BH3-only antagonist Bim. Dev. Cell1 (2001) 645-653.
14. Sattler, M., Liang, H., Nettesheim, D., Meadows, R. P., Harlan, J. E., Eberstadt, M., Yoon, H. S., Shuker, S. B., Chang, B. S. and Minn, A. J. Structure of Bcl-xLBak peptide complex: recognition between regulators of apoptosis. Science275 (1997) 983-994.
15. Kelekar A. and Thompson, C. B. Bcl-2-family proteins: the role of the BH3 domain in apoptosis. Trends Cell Biol. 8 (1998) 324-330.
16. Meier, P., Finch A. and Evan, G. Apoptosis in development. Nature6805 (2000) 796-801.
17. Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J. and Hajduk, P. J. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature435 (2005) 677-681.
18. Tan, F. L. and Yin, J. Q. Application of RNAi to cancer research and therapy. Front Biosci. 10 (2005) 1946-1960.
19. Abdelrahim, M., Safe, S., Baker, C. and Abudayyeh, A. RNAi and cancer: Implications and applications. Int. J. RNA Gene Target Res. 2 (2006) 136-152.
20. Akhtar, S. and Benter, I. F. Nonviral delivery of synthetic siRNAs in vivo. J. Clin. Invest. 117 (2007) 3623-3632.
21. Bozkir, A. and Saka, O. M. Chitosan nanoparticles for plasmid DNA delivery: effect of chitosan molecular structure on formulation and release characteristics. Drug Deliv. 11 (2004) 107-112.
22. Mao, H. Q., Roy, K., Troung-Le, V. L., Janes, K. A., Lin, K. Y., Wang, Y., August, J. T. and Leong, K. W. Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J. Control. Release70 (2001) 399-421.
23. Katas, H. and Alpar, H. O. Development and characterisation of chitosan nanoparticles for siRNA delivery. J. Control. Release115 (2006) 216-225.
24. Agnihotri, S. A., Mallikarjuna N. N. and Aminabhavi, T. M. Recent advances on chitosan-based micro-and nanoparticles in drug delivery, J. Control. Release100 (2004) 5-28.
25. Roy, K., Mao, H. Q., Huang, S. K. and Leong, K. W. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat. Med. 5 (1999) 387-397.
26. Jagani, H. V., Josyula, V. R., Hariharapura, R. C., Palanimuthu, V. R. and Gang, S. S. M. Nanoformulation of siRNA silencing Bcl-2 gene and its implication in cancer therapy, Arzneimittel-Forsch. 61 (2011) 577-591.
27. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods65 (1983) 55-63.
28. Denizot, F. and Lang, R. Rapid colorimetric assay for cell growth and survival: Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J. Immunol. Methods89 (1986) 271-277.
29. Mullis, K. B. Process for amplifying nucleic acid sequences. Google Patents (1987).
30. Mullis, K. B., Faloona, F. A., Scharf, S. J., Saiki, R. K., Horn, G. T. and Erlich, H. Specific enzymatic amplification of DNA in vitro: the polymerase chain reaction. Cold Spring Harbor Symp. Quant. Biol. 51 (1986) 263-273.
31. Lanciotti, R. S., Calisher, C. H., Gubler, D. J., Chang, G J. and Vorndam, A. V. Rapid detection and typing of dengue viruses from clinical samples by using reverse transcriptase-polymerase chain reaction. J. Clin. Microbiol. 30 (1992) 545-560.
32. Burnette, W. N. Western blotting: Electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal. Biochem. 112 (1981) 195-203.
33. De Martimprey, H., Bertrand, J. R., Fusco, A., Santoro, M., Couvreur, P., Vauthier, C. and Malvy, C. siRNA nanoformulation against the ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma. Nucleic Acids Res. 36 (2008) e2-e2.
34. Goodsell, D. S. The molecular perspective: Bcl-2 and apoptosis. The Oncologist7 (2002) 259-260.
35. Ma, W. W. and Adjei, A. A. Novel agents on the horizon for cancer therapy. CA Cancer J. Clin. 59 (2009) 111-137.
36. Howard, K. A., Rahbek, U. L., Liu, X., Damgaard, C. K., Glud, S. Z., Andersen, M. A., Hovgaard, M. B., Schmitz, A., Nyengaard, J. R. and Besenbacher, F. RNA interference in vitro and in vivo using a chitosan/siRNA nanoparticle system. Mol. Ther. 14 (2006) 476-484.
37. Lee, D., Zhang, W., Shirley, S. A., Kong, X., Hellermann, G. R., Lockey, R. F. and Mohapatra, S. S. Thiolated chitosan/DNA nanocomplexes exhibit enhanced and sustained gene delivery. Pharm. Res. 24 (2007) 157-167.
38. Verma, N. K., Davies, A. M., Long, A., Kelleher, D. and Volkov, Y. STAT3 knockdown by siRNA induces apoptosis in human cutaneous T-cell lymphoma line Hut78 via downregulation of Bcl-xL. Cell. Mol. Biol. Lett. 15 (2010) 342-355.
39. Akhtar, S. and Benter, I. F. Nonviral delivery of synthetic siRNAs in vivo. J. Clin. Invest. 117 (2007) 3623-3643.
40. Mao, S., Sun, W. and Kissel, T. Chitosan-based formulations for delivery of DNA and siRNA. Adv. Drug Delivery Rev. 62 (2010) 12-27.
41. Dass, C. R. and Choong, P. F. M. The use of chitosan formulations in cancer therapy. J. Microencapsul. 25 (2008) 275-279.
42. De La Fuente, M., Ravi, A. M., Paolicelli, P., Sanchez, A., Seijo, B. and Alonso, M. J. Chitosan-based nanostructures: a delivery platform for ocular therapeutics. Adv. Drug Delivery Rev. 62 (2010) 100-117.
43. Kim, T. H., Jiang, H. L., Jere, D., Park, I. K., Cho, M. H., Nah, J. W., Choi, Y. J., Akaike, T. and Cho, C. S. Chemical modification of chitosan as a gene carrier in vitro and in vivo. Prog. Polym. Sci. 32 (2007) 726-753.
44. Spandana, K., Hitesh, J., Vasanth, R. P., Jesil, M. A., Mallikarjuna, R. C. and Venkata R. J. In vitro and in vivo evaluation of the efficacy of nanoformulation of siRNA as an adjuvant to improve the anticancer potential of cisplatin. Exp. Mol. Pathol. 2012; http://dx. doi. org/10. 1016/j. yexmp. 2012. 10. 007.